Clinical value of PET/CT's SUV max at baseline, early follow-up, and end of treatment reevaluation as a prognostic factor in small cell lung cancer patients with extended disease.

e18558 Background: Patients with Small Cell Lung Cancer (SCLC) have been staged by the two-stage system. This system defines limited disease (LD) when is confined to ipsilateral hemithorax that can be encompassed within tolerable radiation field; extended disease (ED) is defined as the disease extending outside the hemithorax. The IASLC recommended that TNM staging should be used in SCLC including clinical trials. However these systems have shown poor correlation between clinical findings and the pathological results. Objectives: Evaluate prognostic factors as age, ECOG and PET CT’s SUV max at base line, early follow up and end of treatment reevaluation; and their correlation with Overall survival (OS) and Progression free survival (PFS). Methods: Prospectively were recruited patients with histologically confirmed SCLC and ED and were evaluated with basal PET CT, early follow up (PET CT after 2 cycles of Platinum based chemotherapy) and end of treatment assessment with a PET CT after 6 cycles. Comprehensi...